Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Performance Status and Influencing Factors During Second-Line Treatment With Pemetrexed in Patients With Stage III/IVNon Small Cell Lung Cancer

NCT00540241 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00540241
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00540241 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Performance Status and Influencing Factors During Second-Line Treatment With Pemetrexed in Patients With Stage III/IVNon Small Cell Lung Cancer
Lead sponsor
Eli Lilly and Company
Phase
Observational
Overall status
Completed
Start date
September 30, 2007
Completion date
March 31, 2010
Enrollment
542 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer